SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Acorda Therapeutics Inc. -- Ignore unavailable to you. Want to Upgrade?

To: kenhott who wrote (37)8/4/2009 4:15:39 PM
From: idos  Read Replies (1) | Respond to of 120
 
Importantly, these "relapses" improved when patient went back on fampridine in the extension trials.



To: kenhott who wrote (37)8/4/2009 4:18:30 PM
From: Arthur Radley  Read Replies (1) | Respond to of 120
 
Ken,
Maybe I don't understand the ACOR drug ..it was my understanding the drug helped patients with mobility, not 'relapse'. Plus, it makes sense that AEs would develop if the drug was working and a patient stopped dosing.

IMO, the dip today will give one their final opportunity to buy before FDA takes action.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News